Orexigen Sheds LIGHT On Potential CV Benefit For Contrave
Executive Summary
The biotech disclosed in an SEC filing that its obesity drug may actually provide a cardiovascular benefit to patients based on early results from an ongoing outcomes study.
You may also be interested in...
CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee March 29 voted 17-6 that all obesity drugs should be vetted for cardiovascular risk, but some could rely on a meta-analysis rather than an outcomes trial.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.